Member Info for ThinShins

Soonbetime - what you just said is exactly my thoughts also, by the time SNG001 will be ready for market there will most likely be other treatments also coming to market and like you mentioned most of the western world will be fully vaccinated with 2 doses and potentially a booster targeted at variants of concern. The market in the developed world will be minuscule and the treatment won’t be feasible for poorer nations. We are left hoping countries will stockpile but I can’t see that happening the world is forgetful and once the pandemic passes nobody will care. There’s also no proof SNG001 can treat other viruses so if there is another pandemic let’s hope for the sake of humanity the company has been bought out because my faith in the company is shot after watching that presentation.

Gkb47, fully agree. Other than the obv one of the reasons was that I wanted to invest in a company that would save thousands of lives but reality is that this is now a fairy tale now due to vaccines. By the time readout for phase 3 is ready majority of western world will have been fully vaccinated with both shots and potentially a 3rd booster targeted at variants. Case numbers and hospitalisations will be minuscule.

On your point of big pharmas sniffing around I also agree, many on here have said there are big pharmas in negotiations with sng but I’m still yet to see any evidence to support this claim.

Going to assess my position over this weekend to sell out or hold.

Matterhorn, I get that but surely if the company viewed home use as an “insurance policy” and that it wants “fires to put out” they as the owners of the treatment should have pushed to be in activ-3 if they knew this is where the treatment would be most effective, surely the FDA would consider it, just because the FDA invite you doesn’t mean it’s their way or the highway surely synairgen should have put their case forward for activ3, yes we already have a phase 3 for hospitalised patients but who knows when we will see the results, recruitment is not at sprinting level more so of a gentle walk.

Thanks Matterhorn and Mike109, the thing that is baffling me is RM has stated the Home arm was an "insurance policy" so why enrol in ACTIV-2, surely they should have pushed to be in ACTIV-3 which is for hospitalised patients.

ACTIV-2 has a cohort of anyone with a positive test aged 18+, this is quite different to SG016 home trial which was anyone aged 50+ with a high-risk comorbidity and even then we didn't see blockbuster results.

In light of todays RNS, how do you all feel about our ACTIV-2 trial? Do you think we are in jeopardy of not progressing to ACTIV-2 phase 3 seeing as SNG001 looks to be most effective in Hospitalised patients.

Makes me wonder that if the home trial was a "insurance policy" why were we enrolled into ACTIV-2 and not ACTIV-3? Is it possible that after we hear news on initial 220 patients in phase 2 ACTIV-2 we can be moved onto ACTIV-3 phase 3?

In todays RNS, mentioned that readout for sprinter in H2, is this calendar year or fiscal year? Apologies if daft question

In light of todays RNS, do you think this has put our ACTIV-2 trial in jeopardy of not progressing to phase 3, seeing as SNG001 seems to be most effective in hospitalised patients?

Thanks AJ, how do you know that EUA will only be approved on P3 pivotal and nothing else, do you have any info to back up this claim?

Once we have news on Activ2 and Home Trial, overall we have data set of approx. 440 patients. Bearing this in mind, is it possible a meta-analysis can be carried out by regulatory bodies to grant EUA based on data from 440 patients on the assumption there are no hiccups with safety or efficacy?

Hospital arm - 100
Home arm - 120
Activ-2 - 220

I think the target for final dosing for International P3 is June

Oak, I agree that behind the scenes there is most likely some form of negotiations taking place with big pharma cos, do we have any evidence to suggest this is actively going on?

UK - Home Trial results expected by end of June. (Could be released any day now)

USA - Activ-2, awaiting if our phase 2 will progress to phase 3 ( this news could also drop anytime now)

International - Phase 3, recruitment ongoing.

Scinv - I think Professor Tom Wilkinson is on it, no need to worry. I think he is more than capable of arranging trials in a manner most appropriate for our treatment. Unless you think he is out of his depth? I think he knows a lot more about interferon than any of us here on this board put together.

Do we have a timeline as to when we are expected to have an update in regards to ACTIV-2 and if we will be progressing to P3?

News on this front has been pretty sparse, so I'm assuming things are on track otherwise we would have been given the boot by now.

Andrewpcapp, the confusion has possibly come about as most of us were expecting home trial news based on results gathered after the 28 day follow up, as was done for the hospital arm however it now seems they are waiting for 90 day follow up to include data in relation to long coivid (90 days was reached yesterday).

Nothing substantial though...

"ACTIV-2, which is focused on outpatients, has since been expanded to evaluate a
combination monoclonal antibody therapy, BRII-196 and BRII-198, as well as three
investigational therapeutics: SNG001, an inhalable beta interferon; AZD7442, an investigational
long-acting antibody combination; and camostat mesilate, an orally administered molecule that
may block SARS-CoV-2 from entering cells."

https://translate.google.co.uk/translate?hl=en&sl=sw&u=https://www.otosection.com/tildo-kuanza-majaribio-ya-mwisho-ya-dawa-ya-corona/&prev=search&pto=aue

Corona virus: kenya launches anti-corona drug trial. all agreements reached on the last day of the european transfer window. bbc news, swahili. The drug testing company synairgen is one of the fastest tests ever launched by the government. The program, known as the accord as it is known, aims to create a new drug for patients. Kenyan scientists have teamed up with their international counterparts in an effort to find a cure for covid 19 disease, by experimenting with three drugs. Kenya is preparing to launch the first covid 19 vaccine trial within its borders. The trials will involve health care providers and health professionals. Corona vaccine trials have been resumed after the exercise was temporarily suspended. at the same time the number of infections continues to rise in several countries around the world.

gggg21 cant see anything new worth of note in this, from my initial skim through only mentions that SNG001 being trialled which we've known for a while, am I missing something?

Saint7, how does the chap who tweeted that know that SNG001 is being used in Kenya? The article linked in the twitter thread does not mention interferons or SNG001 again am I missing something?

If I recall correctly, the Danish were saying the blood clotting issues with vaccines could be linked with the method of how the jab is injected. Dr John Campbell in one of his videos also referenced this and explained there's usually 2 common methods, aspiration and non-aspiration.

Aspiration meaning once the needle is inserted the plunger is pulled back and inspected to see if any blood has been drawn in in. If it has drawn blood into the syringe it means the vaccine will be entering the bloodstream which is not meant to happen and should be reattempted.

Non-aspiration is when this check does not occur and is the more commonly practiced, so some people maybe getting the vaccine injected into their bloodstream which is a possible reason for the blood clotting.

I agree MrCosts, it really is a shame that it is taking this long to progress even though we are a UK company, with UK trials backed by UK health authorities, yet we are still away off from EUA, on top of this it seems that sentiment has shifted dramatically in regards to home trial results being inconclusive due to not a strong enough signal to demonstrate efficacy.

Mainstream media will likely portray this as negative and further damage the SP as we were all expecting results better than the hospital Arm due to the belief IFN is more effective early.

We will then be clutching at Activ2 as our phase 3 is no where near close to completing recruitment.

Even then I'm not sure how we will hold up in activ2, seeing as the cohort is open for anyone above 18 who has tested positive. (not targeted to people with co-morbidities or IFN deficiencies), how do you guys and girls see activ2 playing out after the recent "putting out fires" comment by RM?

I really was buzzing hoping our drug would treat thousands here in the UK and abroad and be part of it by investing.

Please do correct me on any misunderstanding I may have, thanks.